6 assets in Esophageal Small Cell Neuroendocrine Carcinoma

Therapeutic assets addressing Esophageal Small Cell Neuroendocrine Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Adebrelimab Esophageal Small Cell Neuroendocrine Carcinoma	Zhangzhou Municipal Hospital	P2	CCC (53)
Carboplatin Esophageal Small Cell Neuroendocrine Carcinoma	Zhangzhou Municipal Hospital	P2	CCC (53)
Cis-Diamminedichloroplatinum Ii Esophageal Small Cell Neuroendocrine Carcinoma	Zhangzhou Municipal Hospital	P2	CCC (53)
Etoposide Esophageal Small Cell Neuroendocrine Carcinoma	Fujian Cancer Hospital	P2	CCC (53)
Serplulimab Esophageal Small Cell Neuroendocrine Carcinoma	Fujian Cancer Hospital	P2	CCC (53)
Toripalimab Esophageal Small Cell Neuroendocrine Carcinoma	Sun Yat-sen University	P2	CCC (53)